HKU Scholars Hub: Browsing DSpace

Browsing by Author Chang, TT

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 6 to 25 of 26 < previous next >

Title	Author(s)	Issue Date	Views
EDP-514, a potent pangenotypic class ii hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B infected patients Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Yuen, RMF Chuang, W-L Peng, C-Y Jeng, WJ Su, W-W Chang, TT Chen, CY Hsu, Y-C De La Rosa, G Ahmad, A Luo, E Conery, A Adda, N	2021
Effects of extended lamivudine therapy in asian patients with chronic hepatitis B Journal:Gastroenterology	Liaw, YF Leung, NWY Chang, TT Guan, R Tai, DI Ng, KY Chien, RN Dent, J Roman, L Edmundson, S Lai, CL	2000	181
Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage Journal:Hepatology	Wu, IC Lai, CL Bui Han, SH Han, KH Gordon, SC Chao, YC Tan, CK Sievert, W Tanwandee, T Xu, D Neo, BL Chang, TT	2010	158
Efficacy of entecavir in nucleoside-naefve patients with mildly elevated ALT Journal:Gastroenterology	Gordon, SC Han, SH Chang, TT Lai, CL Han, KH Chao, YC Tan, CK Sievert, W Tanwandee, T Neo, BL	2008	114
Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B Journal:Hepatology	Chang, TT Lai, CL Yoon, SK Lee, SS Coelho, HSM Carrilho, FJ Poordad, F Halota, W Horsmans, Y Tsai, N Zhang, H Tenney, DJ Tamez, R Iloeje, U	2010	341
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B Journal:New England Journal of Medicine	Lai, CL Shouval, D Lok, AS Chang, TT Cheinquer, H Goodman, Z DeHertogh, D Wilber, R Zink, RC Cross, A Colonno, R Fernandes, L	2006	202
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy Journal:Hepatology	Leung, NWY Lai, CL Chang, TT Guan, R Lee, CM Ng, KY Lim, SG Wu, PC Dent, JC Edmundson, S Condreay, LD Chien, RN	2001	172
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B Journal:Journal of Gastroenterology and Hepatology	Chang, TT Lai, CL Chien, RN Guan, R Lim, SG Lee, CM Ng, KY Nicholls, GJ Dent, JC Leung, NWY	2004	173
Hepatitis B Surface Antigen Loss in Antiviral-treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-naive Patients Treated with Entecavir (ETV) or lamivudine (LVD) Proceeding/Conference:Hepatology	Gish, R Chang, TT Lai, CL de Man, R Gadano, A Poordad, F Zhu, J Yang, J Brett-Smith, H	2006	143
Hepatitis B virus with primary resistance to adefovir Journal:New England Journal of Medicine	Chang, TT Lai, CL	2006	134
Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901 Proceeding/Conference:Hepatology	Liaw, YF Chang, TT Wu, SS Schiff, ER Han, KH Lai, CL Safadi, R Lee, SS Halota, W Goodman, ZD Zhang, H Hindes, R Iloeje, U Beebe, S Kreter, B	2008	142
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Journal:Hepatology	Chang, TT Liaw, YF Wu, SS Schiff, E Han, KH Lai, CL Safadi, R Lee, SS Halota, W Goodman, Z Chi, YC Zhang, H Hindes, R Iloeje, U Beebe, S Kreter, B	2010	162
Long-term entecavir treatment for up to 5 years in Asians with HBEAG-positive nucleos(T)ide naïve chronic hepatitis B: results from ETV-022 and -901 Proceeding/Conference:Hepatology	Pan, C Tong, MJ Kowdley, KV Hu, KQ Chang, TT Lai, CL Yoon, SK Lee, SS Cohen, DS Tang, H Tsai, N	2010	97
Long-Term Histologic Improvement with Entecavir (ETV) Therapy in Patients with Chronic Hepatitis B (CHB) from Japanese and Worldwide Development Programs Proceeding/Conference:Gastroenterology	Liaw, YF Chang, TT Wu, SS Schiff, ER Kan, KH Lai, CL Safadi, R Lee, SS Halota, W Goodman, ZD Zhang, H Iloeje, UH Beebe, S Kreter, B Ishikawa, H Katano, Y Takaguchi, K Omata, M	2009	67
Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B Journal:Journal of Viral Hepatitis	Gish, RG Chang, TT Lai, CL De Man, R Gadano, A Poordad, F Yang, J BrettSmith, H Tamez, R	2010	91
Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes Proceeding/Conference:Hepatology	Gish, RG Chang, TT Lai, CL De Man, RA Poordad, F Xu, D Brett-Smith, H Harris, M Iloeje, U Tang, H	2009	59
A one-year trial of lamivudine for chronic hepatitis B Journal:New England Journal of Medicine	Lai, CL Chien, RN Leung, NWY Chang, TT Guan, R Tai, DI Ng, KY Wu, PC Dent, JC Barber, J Stephenson, SL Gray, DF	1998	155
Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir Journal:Antiviral Therapy	Gish, RG Chang, TT Lai, CL de Man, RA Gadano, A Llamoso, C Tang, H	2013	35
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy Journal:Journal of Hepatology	Shouval, D Lai, CL Chang, TT Cheinquer, H Martin, P Carosi, G Han, S Kaymakoglu, S Tamez, R Yang, J Tenney, D BrettSmith, H	2009	169
Tenofovir alafenamide (TAF) compared with Tenofovir Dispoproxil Fumarate (TDF) in patients with chronic HBV: week 96 efficacy and safety results in Chinese patients enrolled in 2 overseas phase 3 studies Proceeding/Conference:Chinese Infectious Disease and Hepatology Conference	Seto, WKW Fung, S Hou, J Pan, C Chuang, WL Chang, TT Hui, AJ Chen, CY Ma, X Tam, E Tsang, TY Yang, J Flaherty, JF Gaggar, A Mo, S Tong, M Kao, JH Chan, HL	2017	123

Showing results 6 to 25 of 26 < previous next >